# A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants

> **NCT03403348** · PHASE1 · COMPLETED · sponsor: **Janssen BioPharma, Inc.** · enrollment: 130 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-64417184
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03403348
- **Lead sponsor:** Janssen BioPharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-09
- **Primary completion:** 2019-11-24
- **Final completion:** 2019-11-24
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2020-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03403348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03403348, "A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03403348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*